Ensayo aleatorizado abierto sobre la eficacia y la seguridad del zanidatamab en combinación con el tratamiento habitual frente a solo tratamiento habitual para el cáncer de vías biliares avanzado positivo para HER2.
Datos básicos
- Código:
- JZP598-302
- Protocolo:
- JZP598-302
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2024
- Año de finalización:
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study.
Segui-Solanes, Carlos; (...); Borras-Blasco, Joaquin
Article. 10.1016/j.farma.2024.08.002. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study.
Xu, Caiming; (...); Goel, Ajay
Article. 10.1158/1078-0432.CCR-24-1934. 2025
Cefiderocol pharmacokinetics in critically ill patients undergoing ECMO support.
Marín-Cerezuela M; (...); Ramirez P
Letter. 10.1186/s13054-024-05126-4. 2024
Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.
Megias-Vericat, Juan E; (...); Yan, Songkai
Article. 10.1080/13696998.2025.2474886. 2025
Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.
Megias-Vericat, J E; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2024.109122. 2024
Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).
Marquez-Rodas, Ivan; (...); Berrocal, Alfonso
Article. 10.1093/neuonc/noae116. 2024
Fibrillary glomerulonephritis: more frequent than it seems? The diagnostical importance of immunohistochemistry.
Viejo-Boyano I; (...); Hernández-Jaras J
Letter. 10.1016/j.nefroe.2023.05.022. 2024
FibroScan compared to liver biopsy for accurately staging recurrent hepatic steatosis and fibrosis after transplantation for MASH.
Martinez-Arenas, Laura; (...); Berenguer, Marina
Article. 10.1111/liv.16085. 2024
First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas
Gonzalez-Lopez, Jose Antonio; (...); Pousa, Antonio Lopez
Meeting Abstract. https://doi.org/10.1016/j.annonc.2023.09.1161. 2024
Glomerulonefritis fibrilar: ¿Más frecuente de lo que parece? La importancia de la inmunohistoquímica en el diagnóstico
Viejo-Boyano, Iris; (...); Hernandez-Jaras, Julio
Editorial Material. 10.1016/j.nefro.2023.05.001. 2024
HepatoPredict Accurately Selects Hepatocellular Carcinoma Patients for Liver Transplantation Regardless of Tumor Heterogeneity
Andrade, Rita; (...); Cardoso, Joana
Article. 10.3390/cancers17030500. 2025
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
Rodríguez-Lescure Á; (...); de la Haba-Rodriguez J
Article. 10.1007/s12094-024-03411-w. 2024
IDENTIFICATION OF CANDIDATES FOR MASLD TREATMENT WITH INDETERMINATE VIBRATION- CONTROLLED TRANSIENT ELASTOGRAPHY
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Meeting Abstract. 2024
Identification of Candidates for MASLD Treatment With Indeterminate Vibration-Controlled Transient Elastography.
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Article. 10.1016/j.cgh.2024.10.014. 2024
LIPID DROPLET MORPHOLOGY JUSTIFIES DISCORDANCES BETWEEN HEPATIC STEATOSIS GRADES AND MRI PROTON DENSITY FAT FRACTION
Marti-Aguado, David; (...); Marti-Bonmati, Luis
Meeting Abstract. 2024
Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.
Rodríguez MA; (...); Chimeno-Hernández A
Article. 10.1016/j.thromres.2024.109181. 2024
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol
Salazar, Juliana; (...); Sebio, Ana
Article. 10.3390/pharmaceutics16121585. 2024
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).
Martin-Broto J; (...); Hindi N
Article. 10.1200/JCO.24.00358. 2024
Polyribonucleotide phosphorylase is overexpressed in hepatocellular cancer, promoting epithelial phenotype maintenance and tumor progression
Revert-Ros, Francisco; (...); Hernandez-Andreu, Jose Miguel
Article. 10.1016/j.prp.2024.155713. 2024
Precision medicine in metastatic colorectal cancer: targeting KRAS G12C mutation
Article. 10.21037/tgh-24-28. 2024
Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing.
Munoz Martin, Andres J; (...); Hernandez-Presa, Miguel Angel
Article. 10.1007/s12094-024-03586-2. 2024
Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study.
López Muñoz AM; (...); Martín Gómez T
Article. 10.1007/s12094-024-03630-1. 2024
Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain
Alvarez-Gallego, Rafael; (...); Cubillo, Antonio
Article. 10.1177/17588359241309828. 2025
Redefining radiologic responses (RR) in solid tumors: Shall we brace ourselves for a post-RECIST era? Results from a randomized clinical trial (RCT) on neoadjuvant chemotherapy in high-risk soft-tissue sarcomas (HR-STS) of the trunk or extremities
Vanzulli, Andrea; (...); Gronchi, Alessandro
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.11553. 2024
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.
Vanzulli, A; (...); Gronchi, A
Article. 10.1016/j.esmoop.2025.104299. 2025
SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023).
Arranz Arija, Jose Angel; (...); Gonzalez-Billalabeitia, Enrique
Article. 10.1007/s12094-024-03532-2. 2024
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.
Valladares-Ayerbes M; (...); Lloansí Vila A
Article. 10.1007/s12094-024-03487-4. 2024
Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy.
Pasquali, Sandro; (...); Gronchi, Alessandro
Article. 10.1016/j.ebiom.2024.105220. 2024
The Development of a Non-Invasive Screening Method Based on Serum microRNAs to Quantify the Percentage of Liver Steatosis
Soluyanova, Polina; (...); Jover, Ramiro
Article. 10.3390/biom14111423. 2024
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024